$MRK · Merck & Co., Inc.

Thesis

MRK prints Tue BMO in the middle of a genuine re-rating — stock +23% YTD and +67% over the trailing year, Barclays walked PT to $150 last week, consensus revised higher over 30d, rating mix 19/9/1. Options implied ±3.9% is in line with 4Q realized (market not braced either way). Base case: clean beat to ~$2.03 EPS on Keytruda in-line + Winrevair ramp + Qlex subcutaneous conversion above street model, plus guide narrowed to high end of $65.8-67B rev — that combo prints +2-3% on the same-day dual-pharma tape.

What would flip it

Keytruda single-country volume weakness (China or US) surfaces below street — the 2028 LOE-cliff narrative reasserts and the +23% YTD move partially reverses.

The market's narrative

Merck enters Q2 in the middle of a genuine re-rating — stock +23% YTD, +67% over the trailing year, on the softening view that the 2028 Keytruda LOE cliff is more gradual than the 2023 bear case implied. Barclays raised PT to $150 last week reiterating Overweight; consensus was revised HIGHER over the last 30d on both EPS and rev. Keytruda still ~55% of pharma sales — the print will be scrutinized for Winrevair ramp, Qlex subcutaneous conversion pace, and any pipeline update that further de-risks the post-Keytruda gap.

Where the Street may be wrong

• Consensus revised HIGHER over last 30d is the cleanest tape signal we have — sell-side is walking numbers up INTO the print, which historically correlates with beat-and-guide-raise reactions of +2-4% in big-pharma. Not a moonshot, a compounding trend.
• Qlex (subcutaneous Keytruda, approved late 2025) is the underappreciated LOE-mitigation lever — every % of Q2 volume that converts from IV to Qlex extends the exclusivity clock 4-6 years on that patient. Street models 8-12% conversion in Q2; a print >15% conversion is a 'Keytruda cliff softens' step-function positive.
• Winrevair pulmonary hypertension ramp is the next-most-important non-Keytruda line — Street models Q2 rev ~$400M. Prints >$450M signals faster-than-modeled uptake and the post-Keytruda-gap narrative de-risks another notch.
• Barclays PT walk to $150 (from $140) 8 days pre-print + 19/9/1 rating skew = analyst-side signal cleanly bullish. GLP-1-narrative-crowd-out (LLY dominance) is priced in the multiple already — MRK is being valued as an oncology-franchise play, not a broad-pharma bet.
• Options implied ±3.9% is roughly in line with 4Q realized ~4.2% — market NOT braced for a big move either way. This is a hype_neutral setup where a beat-and-narrow-guide-raise plays out as a +2-3% orderly relief bid, not a squeeze.

Peer read: JNJ Q2 innovative-medicine was strong (Darzalex, Erleada) — supportive for the oncology-franchise narrative that MRK is being repriced on. BMY Opdivo/Reblozyl solid but Eliquis LOE weighing = MRK's LOE-softening narrative gets differentiated. LLY Zepbound/Mounjaro continue crushing = MRK correctly cast as oncology-not-GLP-1 in the tape.

Reasoning

• Base-case print: EPS $2.03 (+2.5% vs $1.98 street), rev $16.40B (+0.4% vs $16.33B). Beat driven by (a) Keytruda expected in-line-to-slight-beat, (b) Winrevair ramp above modeled, (c) Qlex conversion contributing at higher-than-modeled attach rate.
• Consensus revised HIGHER over last 30d + Barclays PT walk to $150 8 days pre-print + rating mix 19/9/1 = analyst-side unambiguously bullish. Historical big-pharma template for this combination is +2-4% on a clean beat and modest guide narrowing at high end.
• Guide narrowing to high end of $65.8-67B rev / $5.04-5.16 EPS band = +2 to +3% reaction. Full raise beyond the band = +4 to +6% (upside tail). Reaffirm middle-of-band = +1% to flat. Base case is narrow-to-high-end which supports the +2% call.
• Same-day dual print with PFE creates a sector-carry effect — if both print clean, cross-name buying carries MRK higher on the tape even beyond the fundamental. If PFE misses badly, that pulls MRK modestly lower on sympathy for 2-3 hours until MRK-specific detail asserts.
• Confidence MEDIUM because Keytruda is ~55% of pharma sales — any single-country volume weakness (China, Japan) that comes in below consensus can swing the reaction. Concentration risk keeps this from HIGH.